Catalent seeks slice of gene therapy market with Paragon buy
Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.
from Reuters: Health News https://reut.rs/2P8hPvS
http://bit.ly/2zwRqiM